Potential therapy discovered for hypophosphatasia, a congenital form of rickets

Researchers at the Burnham Institute for Medical Research, led by José Luis Millán, Ph.D., have demonstrated in mice the first successful use of enzyme replacement therapy to prevent hypophosphatasia (HPP), a primary skeletal disease of genetic origin. This discovery lays the foundation for future clinical trials for HPP patients.

Rickets is a softening of the bones that most commonly results from a lack of vitamin D or calcium and from insufficient exposure to sunlight. Hypophosphatasia is a rare, heritable form of rickets caused by mutations in a gene called TNAP, which is essential for the process that causes minerals such as calcium and phosphorus to be deposited in developing bones and teeth.

The physical presentations of this disorder can vary depending on the specific mutation, with more severe symptoms occurring at a younger age of onset. The most severe form of the disease occurs at birth, which can present with absence of bone mineralization in utero, resulting in stillbirth.

Using a mouse model, José Luis Millán, Ph.D. tested the hypothesis that, when administered from birth, a bone-targeted form of the TNAP gene would ease the skeletal defects of HPP. The Millán laboratory, in collaboration with scientists from Enobia Pharma in Montreal, Canada and from the Shriners Hospitals for Children in St. Louis, Missouri, created a soluble form of human TNAP that had been shown to display a strong attraction to bone tissue. Upon injecting the enzyme into the fat layer under the skin of the mice, the treated mice maintained a healthy rate of growth and apparent well being, as well as normal bone mineral density (BMD) of the skull, femur and spine. In fact, complete preservation of skeletal and dental structures were observed after 15 days, and bone lesions were still not seen after 52 days of treatment.

"While the biochemical mechanism that leads to skeletal and dental defects of HPP is now generally understood," said Dr. Millán, "there is currently no established medical treatment."

Given the success of this therapy in preventing HPP, current efforts in Dr. Millán's laboratory are focused on reversing the bone defects in mice once the disease is quite advanced. Future clinical trials may reveal this as the first promising therapy for patients with this genetic disorder.

This study was published in the Journal of Bone and Mineral Research.

Source: Burnham Institute

Related stories:

Viruses are hidden drivers of ocean's nutrient cycle
Scientists on Wednesday said they had discovered deep-sea viruses to be an unexpectedly potent driver of the so-called carbon cycle that sustains oceanic life and helps dampen global warming.
Alcohol consumption can cause too much cell death, fetal abnormalities
The initial signs of fetal alcohol syndrome are slight but classic: facial malformations such as a flat and high upper lip, small eye openings and a short nose.
Joslin study identifies protein that produces 'good' fat
A study by researchers at the Joslin Diabetes Center has shown that a protein known for its role in inducing bone growth can also help promote the development of brown fat, a "good" fat that helps in the expenditure of energy and plays a role in fighting obesity.
Hydrogels provide scaffolding for growth of bone cells
Hyaluronic hydrogels developed by Carnegie Mellon University researchers may provide a suitable scaffolding to enable bone regeneration. The hydrogels, created by Newell Washburn, Krzysztof Matyjaszewski and Jeffrey Hollinger, have proven to encourage the growth of preosteoblast cells, cells that aid the growth and development of bone. Doctoral student Sidi Bencherif will present this research, Sunday, Aug. 17 at the 236th national meeting of the American Chemical Society in Philadelphia.
Scientists replicate diseases in the lab with new stem cell lines
A set of new stem cell lines will make it possible for researchers to explore ten different genetic disorders—including muscular dystrophy, juvenile diabetes, and Parkinson's disease—in a variety of cell and tissue types as they develop in laboratory cultures.
Complete Neandertal mitochondrial genome sequenced from 38,000-year-old bone
A study reported in the August 8th issue of the journal Cell, a Cell Press publication, reveals the complete mitochondrial genome of a 38,000-year-old Neandertal. The findings open a window into the Neandertals' past and helps answer lingering questions about our relationship to them.
Fruit-fly study adds weight to theories about another type of adult stem cell
It turns out that an old dog - or at least an old fruit-fly cell - can learn new tricks. Researchers at the Stanford University School of Medicine have found that mature, specialized cells naturally regress to serve as a kind of de facto stem cell during the fruit-fly life cycle.
Scientists determine strength of 'liquid smoke' with 3D images
(PhysOrg.com) -- Researchers have created a 3D image of a material referred to as "liquid smoke." Aerogel, also known as liquid smoke or "San Francisco fog," is an open-cell polymer with pores smaller than 50 nanometers in diameter.

News discussion:

Medicine & Health news